GLP-1

News

Generic semaglutide in India, and other weight-loss news

Novo Nordisk is facing generic semaglutide in India, Atrogi is testing a new weight loss approach, and Structure has more data with its oral GLP-1.

News

Novo partners with Hims & Hers again, ending GLP-1 spat

Novo Nordisk and Hims & Hers have set their differences aside, agreeing to work together once again on the sale of GLP-1 agonists.

News

Lilly unveils employer scheme for weight-loss drug Zepbound

Eli Lilly has added another channel to its selling options for obesity therapy Zepbound in the US, launching a programme directed at employers.

News

Can GLP-1 drugs help tackle addiction?

New research has lent weight to the intriguing idea that GLP-1 agonists may help people with substance use disorders break their addiction.

News

FDA ramps up its pushback against compounded GLP-1s

In a move that will please Novo Nordisk and Eli Lilly, the FDA sent warnings to 30 telehealth firms, accusing them of illegally marketing GLP-1 drugs.

News

Novo Nordisk plans €432m investment in Irish GLP-1 plant

Novo Nordisk invests in an Irish plant as it prepares for regulatory approvals of its Wegovy pill outside the US.

Generic semaglutide in India, and other weight-loss news

Novo partners with Hims & Hers again, ending GLP-1 spat

Lilly unveils employer scheme for weight-loss drug Zepbound

Can GLP-1 drugs help tackle addiction?

FDA ramps up its pushback against compounded GLP-1s

Novo Nordisk plans €432m investment in Irish GLP-1 plant

LSX2026: On promise and patience, with Hans Schambye

Using AI-driven synthetic personas to take your insights fur...

GLP-1

Editor's Picks